Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics

Psychedelics companies are all the rage right now. Compass Pathways is working with the magic mushroom compound psilocybin to treat depression. It's has raised $290 million in total. Atai Life Sciences - backed by PayPal co-founder Peter Thiel - brought in $258 million from its IPO. In the tech space, this has not gone unnoticed and the same business models that have been used in other platforms for health and wellness startups are coming to psychedelics.

The latest is Journey Clinical, based out of NYC, which has raised a $3 million seed round led by San Francisco VC firm Fifty Years. Also participating were Neo Kuma Ventures, Palo Santo, PsyMed Ventures, Lionheart Ventures, Christina Sass co-founder of Andela, Edvard Engesaeth, MD co-founder of Nurx and, Hans Gangeskar co-founder of Nurx.

Journey joins other startups in the space looking at psychedelic-assisted psychotherapy, where ketamine is used to treat depression, anxiety, PTSD, and trauma, known as ketamine-assisted psychotherapy (KAP). Miami-based startup NUE Life Health raised a $3.3 million seed round for the same purpose back in June. There is also Field Trip and Mindbloom playing in this space.

These startups are pushing at an open door on depression and anxiety. Pre-COVID-19, the National Center for Health Statistics estimated some 50 million Americans were fighting the afflictions. The pandemic has of course exacerbated this issue, with those figures doubling, by some estimates.

It's still an early market. Journey says the market landscape for legal psychedelic therapies is very disparate, with over a million licensed mental health professionals lacking the infrastructure to offer these treatments as they lack access to prescribing clinicians. On the flip side, patients struggle to find psychotherapists who can prescribe psychedelics as treatment.

Journey says it has a decentralized clinic model" that allows psychotherapists to offer legal psychedelic therapy treatments in their practice, starting with ketamine. The way it works is that Journey takes care of the pharmacology side, while psychotherapists that sign up to the platform take care of the psychotherapy of the patient. The treatment plans are then customized to meet the patient's needs.

Jonathan Sabbagh, co-founder and CEO, was previously diagnosed with PTSD, but after discovering psychedelics, he went back to school to study clinical psychology, and went on to co-found Journey. He said: We are on the verge of a paradigm shift in the field of mental health. Psychedelic-assisted psychotherapies are one of the most promising new means of treatment available; they will allow clinicians to tackle the growing global mental health crisis we are facing."

Speaking to TechCrunch he added: When we asked what was the main bottleneck for therapists to offer KAP to their patients, the #1 response was access to a prescribing doctor. Our alpha test group confirmed that guaranteeing access to a trained medical team and building a robust care management system would solve an essential bottleneck of mainstream adoption for KAP."

Journey has two revenue streams. Psychotherapists pay them a $200 monthly membership fee which gives them access to a number of services including and access to the prescriber, an EHR (achieved through a white label), a KAP training (training materials created by a specialized training company), a profile on Journey's directory, and a community of peers. Patients pay journey for medical services. They pay $250 for the intake consultation and $150 for follow-up consultations.

Ela Madej, Founding Partner at Fifty Years, said: I dream of a world where those of us affected by trauma, anxiety, or depression don't have to fall into learned helplessness. We're lucky that powerful psychedelic treatments for the mind exist, but they need to be delivered responsibly, with proper screening, protocols, and follow-up. We've been incredibly impressed by Journey Clinical's ambitious plan to empower psychotherapists to better treat their existing patients."

The team also comprises Kyle Lapidus MD, Ph.D., who has over 20 years as a board-certified psychiatrist and has extensive experience working with ketamine; and Brigitte Gordon DNP a professor at Columbia University and also works for the Multidisciplinary Association for Psychedelic Studies (MAPS.)